Clinical Trial Update: Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on long-term safety, efficacy, and tolerability of BYM338 in sporadic inclusion body myositis completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sporadic Inclusion Body Myositis

Drugs mentioned

• BYM338

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sporadic Inclusion Body Myositis (sIBM) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2018-04-10